108 2018 Form 10-K Annual Report on Form 10-K for the fiscal year ended December 31, 2018 LOE loss of exclusivity AbbVie AbbVie Inc. MAA Marketing Authorization Application ALL acute lymphoblastic leukemia MCOs Managed Care Organizations Amgen Amgen Inc. mCRC metastatic colorectal cancer Amylin Amylin Pharmaceuticals, Inc. mCRPC metastatic castration-resistant prostate cancer aNDA abbreviated New Drug Application MDL multi-district litigation ASEAN Association of Southeast Asian Nations Mead Johnson Mead Johnson Nutrition Company AstraZeneca AstraZeneca PLC Merck Merck & Co., Inc. Biogen Biogen, Inc. MF myelofibrosis BLA Biologics License Application MPM malignant pleural mesothelioma Cardioxyl Cardioxyl Pharmaceuticals, Inc. MSI-H high microsatellite instability CERCLA U.S. Comprehensive Environmental Response, Compensation and Liability Act mUC metastatic urothelial carcinoma Celgene Celgene Corporation NAV net asset value cGMP current Good Manufacturing Practices Nektar Nektar Therapeutics CHMP Committee for Medicinal Products for Human Use NDA New Drug Application CML chronic myeloid leukemia Nitto Denko Nitto Denko Corporation Cormorant Cormorant Pharmaceuticals NKT natural killer T CPPIB CPPIB Credit Europe S.A.R.L., a Luxembourg private limited liability company Novartis Novartis Pharmaceutical Corporation CRC colorectal cancer NSCLC non-small cell lung cancer CytomX CytomX Therapeutics, Inc. NVAF non-valvular atrial fibrillation dMMR DNA mismatch repair deficient OIG Office of Inspector General of the U.S. Department of Health and Human Services DSA Distribution Services Agreement Ono Ono Pharmaceutical Co., Ltd. EC European Commission OTC Over-the-counter EMA European Medicines Agency Otsuka Otsuka Pharmaceutical Co., Ltd. EPO European Patent Office PAD Protein/Peptidyl Arginine Deiminase EPS earnings per share Padlock Padlock Therapeutics, Inc. ERISA Employee Retirement Income Security Act of 1974 PBMs Pharmacy Benefit Managers EU European Union PD-1 programmed death receptor-1 FASB Financial Accounting Standards Board PDMA Prescription Drug Marketing Act FCPA Foreign Corrupt Practices Act Pfizer Pfizer, Inc. FDA U.S. Food and Drug Administration PhRMA Code Pharmaceutical Research and Manufacturers of America’s Professional Practices Code Five Prime Five Prime Therapeutics, Inc. Promedior Promedior, Inc. Flexus Flexus Biosciences, Inc. PRP potentially responsible party F-Star F-Star Alpha Ltd. PSA prostate-specific antigen GAAP U.S. generally accepted accounting principles PsiOxus PsiOxus Therapeutics, Ltd. Gilead Gilead Sciences, Inc. R&D Research and Development GlaxoSmithKline GlaxoSmithKline PLC RA rheumatoid arthritis GTN gross-to-net RCC renal cell carcinoma Halozyme Halozyme Therapeutics, Inc. RDP regulatory data protection HCC Hepatocellular carcinoma Reckitt Reckitt Benckiser Group plc HIV human immunodeficiency virus Roche Roche Holding AG HR 3590 The Patient Protection and Affordable Care Act Sanofi Sanofi S.A. IFM IFM Therapeutics, Inc. sBLA supplemental Biologics License Application ImClone ImClone Systems Incorporated SCCHN squamous cell carcinoma of the head and neck IO Immuno-Oncology SCLC small cell lung cancer IPF idiopathic pulmonary fibrosis SEC U.S. Securities and Exchange Commission iPierian iPierian, Inc. SK Biotek SK Biotek Co., Ltd. IPRD in-process research and development the 2012 Plan The 2012 Stock Award and Incentive Plan Janssen Janssen Pharmaceuticals, Inc. U.S. United States JIA Juvenile Idiopathic Arthritis UK United Kingdom LIBOR London Interbank Offered Rate VTE venous thromboembolic Lilly Eli Lilly and Company WTO World Trade Organization Bristol-Myers Squibb Company and its consolidated subsidiaries may be referred to as Bristol-Myers Squibb, BMS, the Company, we, our or us in this 2018 Form 10-K, unless the context otherwise indicates. Throughout this 2018 Form 10-K we have used terms which are defined below: SUMMARY OF ABBREVIATED TERMS